Cargando…
Alpha glucosidase inhibition activity of phenolic fraction from Simarouba glauca: An in-vitro, in-silico and kinetic study
A phenolic rich fraction purified from Simarouba glauca leaves was effective in alpha glucosidase inhibition. The purified fraction named ‘fraction-14’ had shown significant inhibition of yeast alpha glucosidase enzyme activity (IC(50) = 2.4 ± 0.4 μg/mL) when compared to anti-diabetic drug acarbose...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350133/ https://www.ncbi.nlm.nih.gov/pubmed/32671273 http://dx.doi.org/10.1016/j.heliyon.2020.e04392 |
_version_ | 1783557205194178560 |
---|---|
author | Mugaranja, Kirana P. Kulal, Ananda |
author_facet | Mugaranja, Kirana P. Kulal, Ananda |
author_sort | Mugaranja, Kirana P. |
collection | PubMed |
description | A phenolic rich fraction purified from Simarouba glauca leaves was effective in alpha glucosidase inhibition. The purified fraction named ‘fraction-14’ had shown significant inhibition of yeast alpha glucosidase enzyme activity (IC(50) = 2.4 ± 0.4 μg/mL) when compared to anti-diabetic drug acarbose (IC(50) = 2450 ± 24 μg/mL). The purified fraction also had reasonable DPPH (IC(50) = 14.4 ± 0.1 μg/mL) and ABTS (IC(50) = 7.6 ± 0.5 μg/mL) free radical scavenging activity when compared to the standard ascorbic acid. The LC-MS analysis of bioactive ‘fraction-14’ revealed four compounds, eclalbasaponin-v (1), cyanidin-3-O-(2′galloyl)-galactoside (2), kaempferol-3-O-glucoside (3) and kaempferol-3-O-pentoside (4) for the first time in S. glauca in this study. The kinetic study of the ‘fraction-14’ indicates a mixed type of inhibition on the alpha glucosidase enzyme with K(i), 6.2 μg/mL. Docking studies showed promising binding energy for the compounds 2 (-7.769 kJ/mol), 3 (-7.04 kJ/mol) and 4 (-7.127 kJ/mol) against yeast alpha glucosidase which was better than acarbose (-6.867 kJ/mol). In conclusion, the phenolic rich fraction from S. glauca possessing good in-vitro antioxidant property and alpha glucosidase enzyme inhibition potential along with mixed inhibition kinetics. Also, better binding energy of compounds (1, 2 & 3) appears to contain potential lead-molecule for antidiabetic therapy. |
format | Online Article Text |
id | pubmed-7350133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-73501332020-07-14 Alpha glucosidase inhibition activity of phenolic fraction from Simarouba glauca: An in-vitro, in-silico and kinetic study Mugaranja, Kirana P. Kulal, Ananda Heliyon Article A phenolic rich fraction purified from Simarouba glauca leaves was effective in alpha glucosidase inhibition. The purified fraction named ‘fraction-14’ had shown significant inhibition of yeast alpha glucosidase enzyme activity (IC(50) = 2.4 ± 0.4 μg/mL) when compared to anti-diabetic drug acarbose (IC(50) = 2450 ± 24 μg/mL). The purified fraction also had reasonable DPPH (IC(50) = 14.4 ± 0.1 μg/mL) and ABTS (IC(50) = 7.6 ± 0.5 μg/mL) free radical scavenging activity when compared to the standard ascorbic acid. The LC-MS analysis of bioactive ‘fraction-14’ revealed four compounds, eclalbasaponin-v (1), cyanidin-3-O-(2′galloyl)-galactoside (2), kaempferol-3-O-glucoside (3) and kaempferol-3-O-pentoside (4) for the first time in S. glauca in this study. The kinetic study of the ‘fraction-14’ indicates a mixed type of inhibition on the alpha glucosidase enzyme with K(i), 6.2 μg/mL. Docking studies showed promising binding energy for the compounds 2 (-7.769 kJ/mol), 3 (-7.04 kJ/mol) and 4 (-7.127 kJ/mol) against yeast alpha glucosidase which was better than acarbose (-6.867 kJ/mol). In conclusion, the phenolic rich fraction from S. glauca possessing good in-vitro antioxidant property and alpha glucosidase enzyme inhibition potential along with mixed inhibition kinetics. Also, better binding energy of compounds (1, 2 & 3) appears to contain potential lead-molecule for antidiabetic therapy. Elsevier 2020-07-08 /pmc/articles/PMC7350133/ /pubmed/32671273 http://dx.doi.org/10.1016/j.heliyon.2020.e04392 Text en © 2020 Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Mugaranja, Kirana P. Kulal, Ananda Alpha glucosidase inhibition activity of phenolic fraction from Simarouba glauca: An in-vitro, in-silico and kinetic study |
title | Alpha glucosidase inhibition activity of phenolic fraction from Simarouba glauca: An in-vitro, in-silico and kinetic study |
title_full | Alpha glucosidase inhibition activity of phenolic fraction from Simarouba glauca: An in-vitro, in-silico and kinetic study |
title_fullStr | Alpha glucosidase inhibition activity of phenolic fraction from Simarouba glauca: An in-vitro, in-silico and kinetic study |
title_full_unstemmed | Alpha glucosidase inhibition activity of phenolic fraction from Simarouba glauca: An in-vitro, in-silico and kinetic study |
title_short | Alpha glucosidase inhibition activity of phenolic fraction from Simarouba glauca: An in-vitro, in-silico and kinetic study |
title_sort | alpha glucosidase inhibition activity of phenolic fraction from simarouba glauca: an in-vitro, in-silico and kinetic study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350133/ https://www.ncbi.nlm.nih.gov/pubmed/32671273 http://dx.doi.org/10.1016/j.heliyon.2020.e04392 |
work_keys_str_mv | AT mugaranjakiranap alphaglucosidaseinhibitionactivityofphenolicfractionfromsimaroubaglaucaaninvitroinsilicoandkineticstudy AT kulalananda alphaglucosidaseinhibitionactivityofphenolicfractionfromsimaroubaglaucaaninvitroinsilicoandkineticstudy |